BTK and autoimmune disease: The reasons for the suboptimal effect are not fully understood, but the highly variable PK and pharmacodynamics (PD) seem to limit spebrutinib to continuously reach the in vivo targets.296 In addition, due to the critical role of BTK in the development and function of B cells, BTK has also been confirmed as a potential therapeutic target for autoimmune disorders.